Is Summit Therapeutics a Buy Now?

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. Shares of Summit Therapeutics (SMMT 55.99%) recently jumped in response to positive clinical trial results for its experimental cancer therapy. Results of the phase 3 Harmoni-2 trial suggest newly diagnosed lung cancer patients are better off with its cancer drug candidate, ivonescimab, than the current standard of care, Keytruda from Merck (MRK -2.06%). With global sales that rose 19% last ye ...